Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TAAR1 | Q96RJ0 | 7/20 | 0.66 |
| ▸ | L3MBTL1 | Q9Y468 | 4/20 | 0.56 |
| ▸ | MAPT | P10636 | 3/20 | 0.56 |
| ▸ | HRH1 | P35367 | 1/20 | 0.56 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.56 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.53 |
| ▸ | ATM | Q13315 | 2/20 | 0.46 |
| ▸ | POLB | P06746 | 1/20 | 0.46 |
| ▸ | MEN1 | O00255 | 1/20 | 0.46 |
| ▸ | GAA | P10253 | 1/20 | 0.46 |
| ▸ | THRB | P10828 | 1/20 | 0.46 |
| ▸ | RECQL | P46063 | 1/20 | 0.46 |
| ▸ | BLM | P54132 | 1/20 | 0.46 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.46 |
| ▸ | PLEC | Q15149 | 1/20 | 0.46 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.46 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9038190 | 0.89 | L3MBTL1 (0.53) | TAAR1L3MBTL1MAPTHRH1NPSR1 | |
| SCHEMBL2652372 | 0.87 | L3MBTL1 (0.51) | TAAR1L3MBTL1MAPTHRH1NPSR1 | |
| SCHEMBL3053018 | 0.85 | TAAR1 (0.61) | TAAR1L3MBTL1MAPTHRH1NPSR1 | |
| SCHEMBL469001 | 0.83 | L3MBTL1 (0.60) | TAAR1L3MBTL1MAPTNPSR1ALDH1A1 | |
| SCHEMBL4262567 | 0.83 | L3MBTL1 (0.60) | L3MBTL1MAPTNPSR1ALDH1A1ATM | |
| SCHEMBL31195759 | 0.83 | L3MBTL1 (0.60) | TAAR1L3MBTL1MAPTNPSR1ALDH1A1 | |
| SCHEMBL2911351 | 0.83 | TAAR1 (0.59) | TAAR1L3MBTL1MAPTHRH1NPSR1 | |
| SCHEMBL1253295 | 0.83 | TAAR1 (0.50) | TAAR1L3MBTL1MAPTHRH1NPSR1 | |
| SCHEMBL16499824 | 0.81 | TAAR1 (0.67) | TAAR1HRH1 | |
| SCHEMBL1252234 | 0.80 | TAAR1 (0.56) | TAAR1L3MBTL1MAPTHRH1NPSR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 165 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2074089-B1 | ORGANIC COMPOUNDS | NOVARTIS AG (CH) | 2013-09-18 | — | — | EP | claimed |
| US-20130143824-A1 | COMPOSITIONS AND METHODS FOR ENHANCING APOPTOSIS | GENENTECH, INC. (US) | 2013-06-06 | — | — | US | claimed |
| US-8222248-B2 | Organic compounds | NOVARTIS AG (CH) | 2012-07-17 | — | — | US | claimed |
| US-20120058953-A1 | COMPOSITIONS AND METHODS FOR ENHANCING APOPTOSIS | GENENTECH, INC. (US) | 2012-03-08 | — | — | US | claimed |
| US-20110039324-A1 | COMPOSITIONS AND METHODS FOR ENHANCING APOPTOSIS | GENENTECH, INC. (US) | 2011-02-17 | — | — | US | claimed |
| EP-1745010-B1 | SUBSTITUTED CYCLOHEXYL-1,4-DIAMINE DERIVATIVES | GRUENENTHAL GMBH (DE) | 2009-08-05 | — | — | EP | claimed |
| EP-2074089-A2 | ORGANIC COMPOUNDS | Novartis AG (CH) | 2009-07-01 | — | — | EP | claimed |
| US-20090148921-A1 | Compositions and methods for enhancing apoptosis | GENENTECH, INC. (US) | 2009-06-11 | — | — | US | claimed |
| EP-1590666-B1 | COMPOSITIONS AND METHODS FOR ENHANCING APOPTOSIS | GENENTECH INC (US) | 2008-07-09 | — | — | EP | claimed |
| WO-2008048991-A2 | ORGANIC COMPOUNDS | NOVARTIS AG (CH) | 2008-04-24 | — | — | WO | claimed |
| EP-1590666-A4 | COMPOSITIONS AND METHODS FOR ENHANCING APOPTOSIS | GENENTECH INC (US) | 2006-07-26 | — | — | EP | claimed |
| EP-1590666-A1 | COMPOSITIONS AND METHODS FOR ENHANCING APOPTOSIS | Genentech, Inc. (US) | 2005-11-02 | — | — | EP | claimed |
| US-20040171554-A1 | Compositions and methods for enhancing apoptosis | GENENTECH, INC. | 2004-09-02 | — | — | US | claimed |
| WO-2004072641-A1 | COMPOSITIONS AND METHODS FOR ENHANCING APOPTOSIS | GENENTECH, INC. (US) | 2004-08-26 | — | — | WO | claimed |
| US-20020058788-A1 | Facile deprotection of Fmoc protected amino groups | DISCOVERY PARTNERS INTERNATIONAL, INC. | 2002-05-16 | — | — | US | claimed |
| CN-117343036-A | Isochroman compound, and pharmaceutical composition and application thereof | 江苏联环药业股份有限公司 | 2024-01-05 | — | — | CN | disclosed |
| EP-2318126-B1 | WATER PURIFICATION MEMBRANES WITH IMPROVED FOULING RESISTANCE | UNIV TEXAS (US) | 2018-08-22 | — | — | EP | disclosed |
| WO-1994006451-A1 | SYNTHESIS OF N-SUBSTITUTED OLIGOMERS | CHIRON CORPORATION (US) | 1994-03-31 | — | — | WO | disclosed |
| EP-0540143-A2 | Compounds and methods for inhibition of HIV and related viruses | Medivir Aktiebolag (SE) | 1993-05-05 | — | — | EP | disclosed |
| WO-1993003022-A1 | COMPOUNDS AND METHODS FOR INHIBITION OF HIV AND RELATED VIRUSES | MEDIVIR AB (SE) | 1993-02-18 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020058788-A1 | Facile deprotection of Fmoc protected amino groups | DNPEP, LNPEP, NPEPPS | TAAR1 1082/4885L3MBTL1 668/4885MAPT 1188/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.